Pulmonary Fibrosis: Difference between revisions
Lydia Xenou (talk | contribs) (Created page with " {{subst:Condition}}") |
Lydia Xenou (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<div class="editorbox"> | | ||
<div class="editorbox"> | |||
'''Original Editor '''- Your name will be added here if you created the original content for this page. | '''Original Editor '''- Your name will be added here if you created the original content for this page. | ||
'''Lead Editors''' | '''Lead Editors''' | ||
</div> | </div> | ||
== | == Definition == | ||
Pulmonary Fibrosis (PF) describes a condition in which the lung tissue becomes thickened, stiff, and scarred. The medical terminology used to describe this scar tissue is fibrosis. The alveoli and the blood vessels within the lungs are responsible for delivering oxygen to the body, including the brain, heart, and other organs. As lung tissue becomes scarred and thicker, it is more difficult for the lungs to transfer oxygen into the bloodstream. As a result, the brain, heart, and other organs do not get the oxygen they need to function properly. In some cases, doctors can determine the cause of the fibrosis, but in many cases the cause remains unknown. When there is no known cause for the development of pulmonary fibrosis (and certain radiographic and/or pathologic criteria are met), the disease is called idiopathic pulmonary fibrosis or IPF. More specifically, consensus treatment guidelines from international lung societies define IPF as “a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the histopathologic and/or radiologic pattern of UIP [usual interstitial pneumonia].<br> | |||
If there is a clear association with another illness or the lung fibrosis is the result of a side effect from a medication or an exposure to an agent known to cause PF, then the cause of the disease is no longer considered idiopathic. PF clearly associated with another disease, such as scleroderma or rheumatoid arthritis, would be referred to as pulmonary fibrosis secondary to scleroderma or secondary to rheumatoid arthritis. | |||
[[{{#ev:youtube|J6zM-KhvQuQ}}]] | |||
== Mechanism of Injury / Pathological Process<br> == | == Mechanism of Injury / Pathological Process<br> == | ||
Revision as of 16:57, 25 March 2014
Original Editor - Your name will be added here if you created the original content for this page.
Lead Editors
Definition[edit | edit source]
Pulmonary Fibrosis (PF) describes a condition in which the lung tissue becomes thickened, stiff, and scarred. The medical terminology used to describe this scar tissue is fibrosis. The alveoli and the blood vessels within the lungs are responsible for delivering oxygen to the body, including the brain, heart, and other organs. As lung tissue becomes scarred and thicker, it is more difficult for the lungs to transfer oxygen into the bloodstream. As a result, the brain, heart, and other organs do not get the oxygen they need to function properly. In some cases, doctors can determine the cause of the fibrosis, but in many cases the cause remains unknown. When there is no known cause for the development of pulmonary fibrosis (and certain radiographic and/or pathologic criteria are met), the disease is called idiopathic pulmonary fibrosis or IPF. More specifically, consensus treatment guidelines from international lung societies define IPF as “a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the histopathologic and/or radiologic pattern of UIP [usual interstitial pneumonia].
If there is a clear association with another illness or the lung fibrosis is the result of a side effect from a medication or an exposure to an agent known to cause PF, then the cause of the disease is no longer considered idiopathic. PF clearly associated with another disease, such as scleroderma or rheumatoid arthritis, would be referred to as pulmonary fibrosis secondary to scleroderma or secondary to rheumatoid arthritis.
[[
]]
Mechanism of Injury / Pathological Process
[edit | edit source]
add text here relating to the mechanism of injury and/or pathology of the condition
Clinical Presentation[edit | edit source]
add text here relating to the clinical presentation of the condition
Diagnostic Procedures[edit | edit source]
add text here relating to diagnostic tests for the condition
Outcome Measures[edit | edit source]
add links to outcome measures here (see Outcome Measures Database)
Management / Interventions
[edit | edit source]
add text here relating to management approaches to the condition
Differential Diagnosis
[edit | edit source]
add text here relating to the differential diagnosis of this condition
Key Evidence[edit | edit source]
add text here relating to key evidence with regards to any of the above headings
Resources
[edit | edit source]
add appropriate resources here
Case Studies[edit | edit source]
add links to case studies here (case studies should be added on new pages using the case study template)
Recent Related Research (from Pubmed)[edit | edit source]
Extension:RSS -- Error: Not a valid URL: Feed goes here!!|charset=UTF-8|short|max=10
References[edit | edit source]
References will automatically be added here, see adding references tutorial.
